The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, with incidence rate of 4: 100 thousand per year, according to European data. CLL remains an incurable disease, with most patients over 60 years old. Immunochemotherapy schemes today remain the standard treatment approach f...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2020-05-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/34009/21719 |
| _version_ | 1819004943424552960 |
|---|---|
| author | Irina V. Poddubnaya Tatyana E. Bialik Natalya N. Glonina Olga B. Kalashnikova Kamil D. Kaplanov Valery A. Lapin Nadezhda V. Medvedeva Natalya B. Mikhailova Tatyana N. Moiseeva Evgeniy A. Nikitin Tatyana I. Pospelova Elena A. Stadnik |
| author_facet | Irina V. Poddubnaya Tatyana E. Bialik Natalya N. Glonina Olga B. Kalashnikova Kamil D. Kaplanov Valery A. Lapin Nadezhda V. Medvedeva Natalya B. Mikhailova Tatyana N. Moiseeva Evgeniy A. Nikitin Tatyana I. Pospelova Elena A. Stadnik |
| author_sort | Irina V. Poddubnaya |
| collection | DOAJ |
| description | Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, with incidence rate of 4: 100 thousand per year, according to European data. CLL remains an incurable disease, with most patients over 60 years old. Immunochemotherapy schemes today remain the standard treatment approach for CLL. The advent of novel molecules expands possibilities of treating this disease. Targeted therapy with small molecule inhibitors of Bruton tyrosine kinase (BTK) occupies an important place in the treatment of patients with CLL, both for first-line therapy and for treatment of relapses. The drug acalabrutinib as a highly selective new generation of BTK inhibitor can be considered as an efficient and safe option for first-line therapy and for treatment of the disease relapse in patients with CLL, especially in patients with comorbidity, including cardiovascular diseases (CDV) or risk factors for CVD. |
| first_indexed | 2024-12-20T23:44:55Z |
| format | Article |
| id | doaj.art-376175299edd4a2082a4d8ff2a8cf0a0 |
| institution | Directory Open Access Journal |
| issn | 1815-1434 1815-1442 |
| language | Russian |
| last_indexed | 2024-12-20T23:44:55Z |
| publishDate | 2020-05-01 |
| publisher | IP Habib O.N. |
| record_format | Article |
| series | Современная онкология |
| spelling | doaj.art-376175299edd4a2082a4d8ff2a8cf0a02022-12-21T19:22:58ZrusIP Habib O.N.Современная онкология1815-14341815-14422020-05-01214454710.26442/18151434.2019.4.19072530680The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. ResolutionIrina V. Poddubnaya0Tatyana E. Bialik1Natalya N. Glonina2Olga B. Kalashnikova3Kamil D. Kaplanov4Valery A. Lapin5Nadezhda V. Medvedeva6Natalya B. Mikhailova7Tatyana N. Moiseeva8Evgeniy A. Nikitin9Tatyana I. Pospelova10Elena A. Stadnik11Russian Medical Academy of Continuous Professional EducationThe First Sechenov Moscow State Medical University under Ministry of Health of the Russian FederationKGBUZ Regional Clinical Hospital No. 1 named after prof. S.I. SergeevaClinic “Research Institute of Pediatric Oncology, Hematology and Transplantology named after R.M. Gorbacheva ”FSBEI HE“ First St. Petersburg State Medical University named after Acad. I.P. Pavlova »Ministry of Health of RussiaVolgograd Regional Clinical Oncology CenterDepartment of Health and Pharmacy Yaroslavl RegionState Clinical Hospital City Clinical Hospital No. 31Clinic Research Institute of Pediatric Oncology, Hematology and Transplantology named after R.M. Gorbacheva FSBEI HE First St. Petersburg State Medical University named after Acad. I.P. Pavlova Ministry of Health of RussiaFederal State Budgetary Institution National Medical Research Center for Hematology, Ministry of Health of RussiaGBUZ «City Clinical Hospital named after S.P. Botkin» Department of Health in MoscowFSBEI HE Novosibirsk State Medical University of the Ministry of Health of RussiaFSBEI HE First St. Petersburg State Medical University named after Acad. I.P. Pavlova Ministry of Health of RussiaChronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, with incidence rate of 4: 100 thousand per year, according to European data. CLL remains an incurable disease, with most patients over 60 years old. Immunochemotherapy schemes today remain the standard treatment approach for CLL. The advent of novel molecules expands possibilities of treating this disease. Targeted therapy with small molecule inhibitors of Bruton tyrosine kinase (BTK) occupies an important place in the treatment of patients with CLL, both for first-line therapy and for treatment of relapses. The drug acalabrutinib as a highly selective new generation of BTK inhibitor can be considered as an efficient and safe option for first-line therapy and for treatment of the disease relapse in patients with CLL, especially in patients with comorbidity, including cardiovascular diseases (CDV) or risk factors for CVD.https://modernonco.orscience.ru/1815-1434/article/viewFile/34009/21719chronic lymphocytic leukemiabruton tyrosine kinase inhibitorsimmunochemotherapytargeted therapyibrutinibacalabrutinib |
| spellingShingle | Irina V. Poddubnaya Tatyana E. Bialik Natalya N. Glonina Olga B. Kalashnikova Kamil D. Kaplanov Valery A. Lapin Nadezhda V. Medvedeva Natalya B. Mikhailova Tatyana N. Moiseeva Evgeniy A. Nikitin Tatyana I. Pospelova Elena A. Stadnik The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution Современная онкология chronic lymphocytic leukemia bruton tyrosine kinase inhibitors immunochemotherapy targeted therapy ibrutinib acalabrutinib |
| title | The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution |
| title_full | The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution |
| title_fullStr | The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution |
| title_full_unstemmed | The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution |
| title_short | The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution |
| title_sort | role of second generation bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia resolution |
| topic | chronic lymphocytic leukemia bruton tyrosine kinase inhibitors immunochemotherapy targeted therapy ibrutinib acalabrutinib |
| url | https://modernonco.orscience.ru/1815-1434/article/viewFile/34009/21719 |
| work_keys_str_mv | AT irinavpoddubnaya theroleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT tatyanaebialik theroleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT natalyanglonina theroleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT olgabkalashnikova theroleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT kamildkaplanov theroleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT valeryalapin theroleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT nadezhdavmedvedeva theroleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT natalyabmikhailova theroleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT tatyananmoiseeva theroleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT evgeniyanikitin theroleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT tatyanaipospelova theroleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT elenaastadnik theroleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT irinavpoddubnaya roleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT tatyanaebialik roleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT natalyanglonina roleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT olgabkalashnikova roleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT kamildkaplanov roleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT valeryalapin roleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT nadezhdavmedvedeva roleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT natalyabmikhailova roleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT tatyananmoiseeva roleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT evgeniyanikitin roleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT tatyanaipospelova roleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution AT elenaastadnik roleofsecondgenerationbrutontyrosinekinaseinhibitorsinthetreatmentofchroniclymphocyticleukemiaresolution |